- Home
- NRIX vs MDXG Comparison
NRIX vs MDXG Comparison
Compare NRIX & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- MDXG
- Stock Information
- Founded
- NRIX 2009
- MDXG 2006
- Country
- NRIX United States
- MDXG United States
- Employees
- NRIX N/A
- MDXG N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- NRIX Health Care
- MDXG Health Care
- Exchange
- NRIX Nasdaq
- MDXG Nasdaq
- Market Cap
- NRIX 1.1B
- MDXG 1.0B
- IPO Year
- NRIX 2020
- MDXG N/A
- Fundamental
- Price
- NRIX $9.50
- MDXG $7.05
- Analyst Decision
- NRIX Strong Buy
- MDXG Strong Buy
- Analyst Count
- NRIX 17
- MDXG 3
- Target Price
- NRIX $30.71
- MDXG $12.00
- AVG Volume (30 Days)
- NRIX 942.9K
- MDXG 812.0K
- Earning Date
- NRIX 04-08-2025
- MDXG 04-30-2025
- Dividend Yield
- NRIX N/A
- MDXG N/A
- EPS Growth
- NRIX N/A
- MDXG N/A
- EPS
- NRIX N/A
- MDXG 0.27
- Revenue
- NRIX $56,417,000.00
- MDXG $352,375,000.00
- Revenue This Year
- NRIX $15.73
- MDXG $9.23
- Revenue Next Year
- NRIX N/A
- MDXG $11.49
- P/E Ratio
- NRIX N/A
- MDXG $26.15
- Revenue Growth
- NRIX N/A
- MDXG 5.34
- 52 Week Low
- NRIX $8.18
- MDXG $5.47
- 52 Week High
- NRIX $29.56
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- NRIX 35.33
- MDXG 51.34
- Support Level
- NRIX $9.02
- MDXG $6.53
- Resistance Level
- NRIX $11.56
- MDXG $7.07
- Average True Range (ATR)
- NRIX 0.61
- MDXG 0.33
- MACD
- NRIX -0.07
- MDXG 0.10
- Stochastic Oscillator
- NRIX 14.29
- MDXG 68.03
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.